Division of Gastroenterology and Hepatology, Tokyo Medical University, Kasumigaura Hospital, Ibaraki, Japan.
Hepatol Res. 2008;38(2):123-31. doi: 10.1111/j.1872-034X.2007.00297.x. Epub 2007 Nov 23.
Ursodeoxycholic acid (UDCA) is used in the treatment of cholestatic liver diseases, gallstone dissolution, and for patients with hepatitis C virus infection to ameliorate elevated alanine aminotransferase levels. The efficacy of UDCA treatment has been debated and the mechanisms of action in humans have still not defined. Suggested mechanisms include the improvement of bile acid transport and/or detoxification, cytoprotection, and anti-apoptotic effects. In this review, we summarize the proposed molecular mechanisms for the action of UDCA, especially in hepatocytes, and also discuss the putative future clinical usage of this unique drug.
熊去氧胆酸（UDCA）用于治疗胆汁淤积性肝病、胆结石溶解以及治疗丙型肝炎病毒感染以改善丙氨酸氨基转移酶升高。UDCA 治疗的疗效存在争议，其在人体内的作用机制仍未确定。建议的机制包括改善胆汁酸转运和/或解毒、细胞保护和抗凋亡作用。在这篇综述中，我们总结了 UDCA 作用的提出的分子机制，特别是在肝细胞中的作用机制，还讨论了这种独特药物未来可能的临床应用。
